Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blood-stage CHMI for Transmission Blocking Evaluation
NCT06172686Phase 1Not yet recruiting
- Sponsor
- Ifakara Health Institute
- Start
- Jan 2024
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial in malaria comparing Piperaquine Arm with Doxycycline Arm (2 arms). Primary endpoints: Solicited and unsolicited adverse events and Magnitude of Adverse Events. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
piperaquinedoxycycline
03
Conditions
malaria
Beyond the preview
Go deeper on NCT06172686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06172686.